<p>Belpointe Asset Management LLC 在最近向证券交易委员会（SEC）提交的文件中表示，在第一季度将其在诺和诺德公司（Novo Nordisk A/S，NYSE:NVO - 免费报告）的股份增加了 96.2%。该公司在季度内额外购买了 5,193 股后，持有该公司 10,589 股股票。Belpointe Asset Management LLC 在诺和诺德公司的持股在最近一个季度末价值为 735,000 美元。</p>
<ul>
<li>特朗普 GLP-1 试点计划可能推动诺和诺德和礼来公司的发展</li>
</ul>
<p>其他对冲基金和机构投资者最近也买卖了该公司的股票。Copeland Capital Management LLC 在第一季度将其在诺和诺德公司的持股增加了 184.8%。Copeland Capital Management LLC 现在拥有 393 股该公司的股票，价值 27,000 美元，此前在此期间额外购买了 255 股。North Capital Inc. 在第一季度购买了诺和诺德公司的新股份，价值约 27,000 美元。Park Square Financial Group LLC 在第四季度购买了诺和诺德公司的新股份，价值约 29,000 美元。Stone House Investment Management LLC 在第一季度购买了诺和诺德公司的新股份，价值约 30,000 美元。最后，Disciplina Capital Management LLC 在第一季度将其在诺和诺德公司的持股增加了 162.3%。Disciplina Capital Management LLC 现在拥有 480 股该公司的股票，价值 33,000 美元，此前在此期间额外购买了 297 股。目前，11.54% 的股票由对冲基金和其他机构投资者持有。</p>
<p>获取 <strong>诺和诺德公司</strong> 的提醒：</p>
<h2>诺和诺德公司价格表现</h2>
<p>诺和诺德公司（NYSE NVO）周五开盘价为 54.94 美元。该公司的债务与股本比率为 0.52，速动比率为 0.56，流动比率为 0.78。诺和诺德公司的 52 周低点为 45.05 美元，52 周高点为 138.22 美元。该公司的市值为 2453.1 亿美元，市盈率为 15.09，市盈增长比率为 2.06，贝塔值为 0.66。该股票的 50 日简单移动平均线为 57.96 美元，200 日简单移动平均线为 66.49 美元。</p>
<ul>
<li>MarketBeat 周回顾 – 08/04 - 08/08</li>
</ul>
<p>诺和诺德公司（NYSE:NVO - 获取免费报告）最近于 8 月 6 日（星期三）发布了其财报。该公司报告本季度每股收益为 0.97 美元，超出市场共识预期的 0.93 美元，超出幅度为 0.04 美元。诺和诺德公司的股本回报率为 78.64%，净利润率为 35.60%。该公司本季度的收入为 116.9 亿美元，而分析师预期为 77.51 亿美元。整体来看，股票研究分析师预测诺和诺德公司在当前财政年度将发布 3.84 美元的每股收益。</p>
<h2>诺和诺德公司削减股息</h2>
<p>该公司最近还宣布了一项半年度股息，于 8 月 26 日（星期二）支付。8 月 18 日（星期一）登记的股东获得每股 0.4119 美元的股息。这代表着 240.0% 的股息收益率。该股息的除息日期为 8 月 18 日（星期一）。诺和诺德公司的股息支付比率（DPR）为 22.53%。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>礼来公司 14% 的财报后下滑是否是买入机会？</li>
</ul>
<p>NVO 已成为多份研究分析师报告的主题。BNP Paribas Exane 将诺和诺德公司的评级从 “表现不佳” 上调至 “中性”，并在 8 月 13 日的报告中设定了 54.00 美元的目标价。Sanford C. Bernstein 在周二的研究报告中将诺和诺德公司的评级从 “市场表现” 上调至 “超越市场”。Zacks Research 在 8 月 20 日的研究报告中将诺和诺德公司的评级从 “持有” 下调至 “强烈卖出”。巴克莱在 7 月 30 日的研究报告中重申了对诺和诺德公司股票的 “等权重” 评级。最后，Dbs Bank 在 8 月 22 日的研究报告中将诺和诺德公司的评级从 “强烈卖出” 上调至 “持有”。四位分析师对该股票给予了买入评级，十一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司的共识评级为 “持有”，共识目标价为 81.00 美元。</p>
<p><strong>查看我们最新的 NVO 研究报告</strong></p>
<h2>诺和诺德公司简介</h2>
<p>（免费报告）</p>
<p>诺和诺德公司及其子公司从事药品的研究与开发、制造和分销，业务遍及欧洲、中东、非洲、中国大陆、香港、台湾、北美及国际市场。它分为两个部门，糖尿病与肥胖护理，以及罕见疾病。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票，胜过诺和诺德公司</li>
<li>加拿大债券市场假期：如何投资和交易</li>
<li>特斯拉在美国市场处于 8 年低点……情况会有多糟？</li>
<li>想在下跌趋势中获利？下跌趋势解析。</li>
<li>国会：影响市场的最大交易</li>
<li>10 只最佳航空公司股票推荐</li>
<li>3 家公司在其他公司缩减回购时增加回购</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在诺和诺德公司吗？</h2>
<p>在你考虑诺和诺德公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前买入……而诺和诺德公司并不在名单上。</p>
<p>虽然诺和诺德公司目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

诺和诺德公司

<p>Belpointe Asset Management LLC 在第一季度将其在诺和诺德公司的股份增加了 96.2%，目前持有 10,589 股，价值 735,000 美元。其他机构投资者也增加了他们的持股。诺和诺德的股票开盘价为 54.94 美元，市值为 2453.1 亿美元。该公司报告每股收益为 0.97 美元，超出预期，并宣布每股派发半年度股息 0.4119 美元。分析师对该股票的评级不一，普遍评级为 “持有”，目标价为 81.00 美元</p>

<p>Belpointe Asset Management LLC boosted its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 96.2% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,589 shares of the company's stock after acquiring an additional 5,193 shares during the quarter. Belpointe Asset Management LLC's holdings in Novo Nordisk A/S were worth $735,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Belpointe Asset Management LLC 在最近向证券交易委员会（SEC）提交的文件中表示，在第一季度将其在诺和诺德公司（Novo Nordisk A/S，NYSE:NVO - 免费报告）的股份增加了 96.2%。该公司在季度内额外购买了 5,193 股后，持有该公司 10,589 股股票。Belpointe Asset Management LLC 在诺和诺德公司的持股在最近一个季度末价值为 735,000 美元。</p>
</div><ul>
<li>Trump GLP-1 Pilot Program Could Boost Novo Nordisk &amp; Eli Lilly</li>
</ul>
<div class="lb-trans"><ul>
<li>特朗普 GLP-1 试点计划可能推动诺和诺德和礼来公司的发展</li>
</ul>
</div><p>Other hedge funds and other institutional investors also recently bought and sold shares of the company. Copeland Capital Management LLC boosted its holdings in Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after acquiring an additional 255 shares during the period. North Capital Inc. purchased a new position in Novo Nordisk A/S during the 1st quarter valued at about $27,000. Park Square Financial Group LLC purchased a new position in Novo Nordisk A/S during the 4th quarter valued at about $29,000. Stone House Investment Management LLC purchased a new position in Novo Nordisk A/S during the 1st quarter valued at about $30,000. Finally, Disciplina Capital Management LLC boosted its holdings in Novo Nordisk A/S by 162.3% during the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company's stock valued at $33,000 after acquiring an additional 297 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者最近也买卖了该公司的股票。Copeland Capital Management LLC 在第一季度将其在诺和诺德公司的持股增加了 184.8%。Copeland Capital Management LLC 现在拥有 393 股该公司的股票，价值 27,000 美元，此前在此期间额外购买了 255 股。North Capital Inc. 在第一季度购买了诺和诺德公司的新股份，价值约 27,000 美元。Park Square Financial Group LLC 在第四季度购买了诺和诺德公司的新股份，价值约 29,000 美元。Stone House Investment Management LLC 在第一季度购买了诺和诺德公司的新股份，价值约 30,000 美元。最后，Disciplina Capital Management LLC 在第一季度将其在诺和诺德公司的持股增加了 162.3%。Disciplina Capital Management LLC 现在拥有 480 股该公司的股票，价值 33,000 美元，此前在此期间额外购买了 297 股。目前，11.54% 的股票由对冲基金和其他机构投资者持有。</p>
</div><p>Get <strong>Novo Nordisk A/S</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>诺和诺德公司</strong> 的提醒：</p>
</div><h2>Novo Nordisk A/S Price Performance</h2>
<div class="lb-trans"><h2>诺和诺德公司价格表现</h2>
</div><p>Shares of NYSE NVO opened at $54.94 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $138.22. The firm has a market capitalization of $245.31 billion, a PE ratio of 15.09, a price-to-earnings-growth ratio of 2.06 and a beta of 0.66. The stock's 50-day simple moving average is $57.96 and its 200-day simple moving average is $66.49.</p>
<div class="lb-trans"><p>诺和诺德公司（NYSE NVO）周五开盘价为 54.94 美元。该公司的债务与股本比率为 0.52，速动比率为 0.56，流动比率为 0.78。诺和诺德公司的 52 周低点为 45.05 美元，52 周高点为 138.22 美元。该公司的市值为 2453.1 亿美元，市盈率为 15.09，市盈增长比率为 2.06，贝塔值为 0.66。该股票的 50 日简单移动平均线为 57.96 美元，200 日简单移动平均线为 66.49 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 08/04 - 08/08</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 08/04 - 08/08</li>
</ul>
</div><p>Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The business had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>诺和诺德公司（NYSE:NVO - 获取免费报告）最近于 8 月 6 日（星期三）发布了其财报。该公司报告本季度每股收益为 0.97 美元，超出市场共识预期的 0.93 美元，超出幅度为 0.04 美元。诺和诺德公司的股本回报率为 78.64%，净利润率为 35.60%。该公司本季度的收入为 116.9 亿美元，而分析师预期为 77.51 亿美元。整体来看，股票研究分析师预测诺和诺德公司在当前财政年度将发布 3.84 美元的每股收益。</p>
</div><h2>Novo Nordisk A/S Cuts Dividend</h2>
<div class="lb-trans"><h2>诺和诺德公司削减股息</h2>
</div><p>The firm also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were given a dividend of $0.4119 per share. This represents a dividend yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is 22.53%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项半年度股息，于 8 月 26 日（星期二）支付。8 月 18 日（星期一）登记的股东获得每股 0.4119 美元的股息。这代表着 240.0% 的股息收益率。该股息的除息日期为 8 月 18 日（星期一）。诺和诺德公司的股息支付比率（DPR）为 22.53%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?</li>
</ul>
<div class="lb-trans"><ul>
<li>礼来公司 14% 的财报后下滑是否是买入机会？</li>
</ul>
</div><p>NVO has been the subject of a number of research analyst reports. BNP Paribas Exane upgraded Novo Nordisk A/S from an &#34;underperform&#34; rating to a &#34;neutral&#34; rating and set a $54.00 target price for the company in a report on Wednesday, August 13th. Sanford C. Bernstein raised Novo Nordisk A/S from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating in a research report on Tuesday. Zacks Research lowered Novo Nordisk A/S from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research report on Wednesday, August 20th. Barclays reaffirmed an &#34;equal weight&#34; rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. Finally, Dbs Bank raised Novo Nordisk A/S from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Friday, August 22nd. Four analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of &#34;Hold&#34; and a consensus target price of $81.00.</p>
<div class="lb-trans"><p>NVO 已成为多份研究分析师报告的主题。BNP Paribas Exane 将诺和诺德公司的评级从 “表现不佳” 上调至 “中性”，并在 8 月 13 日的报告中设定了 54.00 美元的目标价。Sanford C. Bernstein 在周二的研究报告中将诺和诺德公司的评级从 “市场表现” 上调至 “超越市场”。Zacks Research 在 8 月 20 日的研究报告中将诺和诺德公司的评级从 “持有” 下调至 “强烈卖出”。巴克莱在 7 月 30 日的研究报告中重申了对诺和诺德公司股票的 “等权重” 评级。最后，Dbs Bank 在 8 月 22 日的研究报告中将诺和诺德公司的评级从 “强烈卖出” 上调至 “持有”。四位分析师对该股票给予了买入评级，十一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司的共识评级为 “持有”，共识目标价为 81.00 美元。</p>
</div><p><strong>View Our Latest Research Report on NVO</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 NVO 研究报告</strong></p>
</div><h2>Novo Nordisk A/S Profile</h2>
<div class="lb-trans"><h2>诺和诺德公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.</p>
<div class="lb-trans"><p>诺和诺德公司及其子公司从事药品的研究与开发、制造和分销，业务遍及欧洲、中东、非洲、中国大陆、香港、台湾、北美及国际市场。它分为两个部门，糖尿病与肥胖护理，以及罕见疾病。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Novo Nordisk A/S</li>
<li>Canada Bond Market Holiday: How to Invest and Trade</li>
<li>Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get?</li>
<li>Want to Profit on the Downtrend? Downtrends, Explained.</li>
<li>Congress: The Biggest Trades Impacting Markets Today</li>
<li>10 Best Airline Stocks to Buy</li>
<li>3 Companies Boosting Buybacks While Others Pull Back</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过诺和诺德公司</li>
<li>加拿大债券市场假期：如何投资和交易</li>
<li>特斯拉在美国市场处于 8 年低点……情况会有多糟？</li>
<li>想在下跌趋势中获利？下跌趋势解析。</li>
<li>国会：影响市场的最大交易</li>
<li>10 只最佳航空公司股票推荐</li>
<li>3 家公司在其他公司缩减回购时增加回购</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=NVO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Novo Nordisk A/S Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在诺和诺德公司吗？</h2>
</div><p>Before you consider Novo Nordisk A/S, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑诺和诺德公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前买入……而诺和诺德公司并不在名单上。</p>
</div><p>While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然诺和诺德公司目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Belpointe 资产管理有限责任公司增加了对诺和诺德公司$NVO 的股票持有量